Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis
Ticlopidine hydrochloride has been shown to reduce the risk of first or recurrent stroke in patients who have experienced a transient ischemic attack, reversible ischemic neurological deficit, recurrent stroke or first stroke. Severe liver dysfunction is a contraindication for its use. Increase in l...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1996-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1996/894752 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568285183344640 |
|---|---|
| author | Sander Jo Veldhuyzen van Zanten C William McCormick |
| author_facet | Sander Jo Veldhuyzen van Zanten C William McCormick |
| author_sort | Sander Jo Veldhuyzen van Zanten |
| collection | DOAJ |
| description | Ticlopidine hydrochloride has been shown to reduce the risk of first or recurrent stroke in patients who have experienced a transient ischemic attack, reversible ischemic neurological deficit, recurrent stroke or first stroke. Severe liver dysfunction is a contraindication for its use. Increase in liver enzymes has been reported with use of this drug, but jaundice is rare. A case of severe ticlopidine-induced hepatitis that was associated with a marked increase in antinuclear antibody (ANA) levels is reported. Physicians prescribing ticlopidine hydrochloride should be aware that a potentially severe acute hepatitis associated with ANA positivity can occur. The drug should be discontinued if signs of liver dysfunction occur. |
| format | Article |
| id | doaj-art-4915b08ed85745299ff8b62434eed032 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1996-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-4915b08ed85745299ff8b62434eed0322025-02-03T00:59:25ZengWileyCanadian Journal of Gastroenterology0835-79001996-01-0110423123210.1155/1996/894752Antinuclear Antibody-Positive Ticlopidine-Induced HepatitisSander Jo Veldhuyzen van Zanten0C William McCormick1Division of Gastroenterology and Division of Neurology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, CanadaDivision of Gastroenterology and Division of Neurology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, CanadaTiclopidine hydrochloride has been shown to reduce the risk of first or recurrent stroke in patients who have experienced a transient ischemic attack, reversible ischemic neurological deficit, recurrent stroke or first stroke. Severe liver dysfunction is a contraindication for its use. Increase in liver enzymes has been reported with use of this drug, but jaundice is rare. A case of severe ticlopidine-induced hepatitis that was associated with a marked increase in antinuclear antibody (ANA) levels is reported. Physicians prescribing ticlopidine hydrochloride should be aware that a potentially severe acute hepatitis associated with ANA positivity can occur. The drug should be discontinued if signs of liver dysfunction occur.http://dx.doi.org/10.1155/1996/894752 |
| spellingShingle | Sander Jo Veldhuyzen van Zanten C William McCormick Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis Canadian Journal of Gastroenterology |
| title | Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis |
| title_full | Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis |
| title_fullStr | Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis |
| title_full_unstemmed | Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis |
| title_short | Antinuclear Antibody-Positive Ticlopidine-Induced Hepatitis |
| title_sort | antinuclear antibody positive ticlopidine induced hepatitis |
| url | http://dx.doi.org/10.1155/1996/894752 |
| work_keys_str_mv | AT sanderjoveldhuyzenvanzanten antinuclearantibodypositiveticlopidineinducedhepatitis AT cwilliammccormick antinuclearantibodypositiveticlopidineinducedhepatitis |